{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:46:58Z","timestamp":1791082018157,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Institute","award":["UL1TR002378"],"award-info":[{"award-number":["UL1TR002378"]}]},{"name":"s"},{"name":"of Health"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.bbmt.2018.06.005","type":"journal-article","created":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T03:43:57Z","timestamp":1528861437000},"page":"2065-2071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0390-9087","authenticated-orcid":false,"given":"Amber B.","family":"Clemmons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianne","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Andrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Sportes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"DeRemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2018.06.005_bib0001","first-page":"763","article-title":"The clinical problem of chemotherapy-induced nausea and vomiting","volume":"30","author":"Rapoport","year":"2016","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0002","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0003","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.critrevonc.2017.02.017","article-title":"Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis","volume":"112","author":"Yoodee","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0004","first-page":"1655","article-title":"The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy","volume":"21","author":"Navari","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0005","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J Support Oncol"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0006","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study","volume":"47","author":"Mizukami","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0007","first-page":"675","article-title":"Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial","volume":"24","author":"Abe","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1756-9966-28-131","article-title":"Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting","volume":"28","author":"Tan","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0009","first-page":"2381","article-title":"Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis","volume":"24","author":"Chiu","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0010","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1038\/srep04813","article-title":"A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"4","author":"Wang","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0011","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/phar.1703","article-title":"Emerging role of olanzapine for prevention and treatment of chemotherapy-induced nausea and vomiting","volume":"36","author":"DeRemer","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0012","first-page":"1001","article-title":"Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review","volume":"24","author":"Chow","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0013","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/postgradmedj-2014-132969","article-title":"Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines","volume":"92","author":"Tageja","year":"2016","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0014","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2017.74.4789","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"35","author":"Hesketh","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0015","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0017","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clml.2017.06.012","article-title":"Olanzapine reduces chemotherapy-induced nausea and vomiting compared with aprepitant in myeloma patients receiving high-dose melphalan before stem cell transplantation: a retrospective study","volume":"17","author":"Trifilio","year":"2017","journal-title":"Clin Lymph Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0018","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1177\/1078155215585190","article-title":"Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant","volume":"22","author":"Clark","year":"2016","journal-title":"J Oncol Pharm Practice"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0019","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bbmt.2012.07.019","article-title":"Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens","volume":"19","author":"Stiff","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0020","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12185-016-2152-6","article-title":"Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: a phase II study","volume":"105","author":"Isoda","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0021","first-page":"607","article-title":"A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation","volume":"25","author":"Nakagaki","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0022","first-page":"303","article-title":"2016 Updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting","volume":"25","author":"Einhorn","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0024","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0025","first-page":"2911","article-title":"Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study","volume":"22","author":"Bechtel","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0026","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1200\/JCO.2013.55.0095","article-title":"Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial","volume":"32","author":"Schmitt","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0027","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0028","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1477-7525-1-46","article-title":"Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy","volume":"1","author":"Ballatori","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0029","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1634\/theoncologist.8-2-187","article-title":"Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control","volume":"8","author":"Schnell","year":"2003","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0030","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/bcp.13322","article-title":"Aprepitant and fosaprepitant drug interactions: a systematic review","volume":"83","author":"Patel","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.10111","article-title":"A double-blind randomized phase II study of 10 versus 5 mg olanzapine for emesis induced by highly emetogenic chemotherapy with cisplatin","volume":"34","author":"Hashimoto","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2018.06.005_bib0032","year":"2009"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118303173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879118303173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:03:39Z","timestamp":1761059019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879118303173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1083879118303173"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.005","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}